Recent research from Calidi Biotherapeutics (as of early 2026) highlights a significant shift toward systemic (whole-body) delivery of oncolytic viruses and progress in their stem-cell-based platforms.Their research and development are currently focused on three primary therapeutic platforms: RedTail, SuperNova, and NeuroNova.1. RedTail Platform (Lead Candidate: CLD-401)This is Calidi’s newest a..